

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings of claims in the application:

Listing of Claims:

Claim 1 (currently amended): A method for inhibiting a condition characterized by monocytic infiltrates, wherein said method comprises administering to a patient a therapeutically effective amount of an MCP-1 receptor antagonist in a suitable pharmaceutical carrier composition, wherein said MCP-1 receptor antagonist is an antibody which binds to an MCP-1 receptor polypeptide comprising SEQ ID NO: 2 or SEQ ID NO: 4, wherein the condition is selected from the group consisting of rheumatoid arthritis, alveolitis and atherosclerosis.

Claim 2-3 (canceled).

Claim 4 (previously presented): The method of claim 1, wherein said pharmaceutical composition contains about 10 µg/ml to about 1 mg/ml of the antagonist.

Claim 5-6 (canceled).

Claim 7 (previously presented): The method of claim 1, wherein said antibody is a monoclonal antibody.

Claims 8-9 (canceled).

Claim 10 (previously presented): A method for inhibiting MCP-1 receptor activation, wherein said method comprises administering to a patient a therapeutically effective amount of an MCP-1 receptor antagonist in a suitable pharmaceutical carrier composition, wherein said MCP-1 receptor antagonist is an antibody which binds to SEQ ID NO: 2 or SEQ ID NO: 4.

Claim 11-12 (canceled).

Appl. No. 10/791,166
Amdt. dated March 17, 2006
Reply to Office Action of November 18, 2005

PATENT

Claim 13 (previously presented): The method of claim 10, wherein said pharmaceutical composition contains about 10 μ g/ml to about 1 mg/ml of the antagonist.

Claim 14-18 (canceled).